AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00357500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Study NCT00357500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT02107586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biceps tenotomy
Description: A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
Study NCT02107586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biceps tenodesis
Description: Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
Study NCT03733223 — intervention group
Intervention type: DRUG
Intervention: Ateptidase
Description: Treatment of ischemic stroke with Ateptidase
Study NCT02425826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
Study NCT02425826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
Study NCT02425826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
Study NCT02425826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Apremilast
Description: At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
Study NCT02425826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Apremilast
Description: At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
Study NCT02178488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol 4000 IU/day for 12 months
Study NCT02178488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
Study NCT03260959 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview by hierarchical evocation's Method
Description: Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
Study NCT01464307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (400 Units)
Description: Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
Study NCT01464307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
Study NCT04000685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga exercise program
Description: Yoga exercise program will be applied two sessions per week, totally eight week.
Study NCT04000685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal stabilization exercise program
Description: Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
Study NCT04000685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic walking program
Description: Aerobic walking program will be applied two sessions per week, totally eight week.
Study NCT03475459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-15 and/or Placebo
Description: The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
Study NCT02065154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03650192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00027
Description: Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
Study NCT02814630 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Xolair
Description: The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
Study NCT00723164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and Midazolam
Description: A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
Study NCT00723164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
Study NCT03970902 — intervention group
Intervention type: OTHER
Intervention: Integrated Osteoporosis Care
Description: Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.
Study NCT03970902 — intervention group
Intervention type: OTHER
Intervention: Care As Usual
Description: No intervention Patients receive care as usual from their family physician
Study NCT02197676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 administration
Description: SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle.
Study NCT05301946 — intervention group
Intervention type: OTHER
Intervention: Outcome Measurements
Description: The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
Study NCT02418416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oocyte double chemical activation
Description: Oocyte double chemical activation
Study NCT00737659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (CellCept® )
Description: Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg\*h\\L) measured on Days 7,14,Months 1,3,6 and 12.
Study NCT00737659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (CellCept® )
Description: Fixed Dose group, MMF dosage will be adjusted based on standard care
Study NCT02448407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Three intraarticular injections of platelet-rich plasma, one each fifteen days
Study NCT02448407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
Study NCT00356941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 60 mg/m2 on day 1 of each week during radiation therapy
Study NCT00356941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
Study NCT00356941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 2 Gy Days 1-5 each week, total dose of 70Gy
Study NCT01594021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelatin 500 mL
Description: intravenous administration
Study NCT01594021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin 50 mL
Description: intravenous administration
Study NCT04824586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting human insulin
Description: Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
Study NCT02692209 — intervention group
Intervention type: DEVICE
Intervention: FFDM Plus DBT
Description: FFDM + DBT Images~FujiFilm Aspire Cristalle System
Study NCT02692209 — intervention group
Intervention type: DEVICE
Intervention: FFDM Alone
Description: FFDM Alone Images
Study NCT01687712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFOLIA
Description: 225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
Study NCT01687712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f® RFF
Description: 225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
Study NCT02987621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
Study NCT02058680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA/IL-2/GM-CSF
Description: In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43.
Study NCT03824665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine Group
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group N:(Nalbuphine group)1 ml saline containing 4mg nalbuphine used instead of normal saline
Study NCT03824665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Group
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline
Study NCT03824665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline.
Study NCT00603759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: 100 mg qid
Study NCT00603759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 cap qid
Study NCT04868812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy
Description: SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy; MonaLisa Touch CO2 fractionated laser
Study NCT02797886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES + VOL
Description: Electrical stimulation is applied in concert with the subject's volitional movement.
Study NCT02797886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES
Description: Electrical stimulation is applied to the subject while they are asked to do nothing.
Study NCT02797886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VOL
Description: The subject initiates and completes the movement without electrical stimulation.
Study NCT00394459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perifix Epidural Anaesthesia Catheter
Description: Epidural Catheter
Study NCT00394459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perifix Epidural Anaesthesia Catheter
Description: Epidural Catheter
Study NCT00394459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perifix Standard
Description: Perifix Standard
Study NCT00394459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perifix New
Description: Perifix New
Study NCT00630630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Study NCT00630630 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00512798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341 (VELCADE)
Description: Dose Levels PS-341 (day 1)~* Level -1 0.7 mg/m2~* Level 1 1.0 mg/m2~* Level 2 1.0 mg/m2~* Level 3 1.3 mg/m2~* Level 4 1.5 mg/m2
Study NCT00512798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide (day 8)~* Level - 1 50 mg/m2~* Level 1 50 mg/m2~* Level 2 75/mg/m2~* Level 3 75 mg/m2~* Level 4 75 mg/m2
Study NCT00512798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Not noted
Study NCT00512798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341 (VELCADE)
Description: 1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
Study NCT00512798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
Study NCT02216461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIBW 2948 BS for oral inhalation
Study NCT02216461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIBW 2948 BS for oral inhalation
Study NCT02216461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIBW 2948 BS for oral inhalation
Study NCT02216461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04354350 — intervention group
Intervention type: DRUG
Intervention: Ramipril
Description: Ramipril dispensing claim is used as the reference
Study NCT04354350 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Description: Telmisartan dispensing claim is used as the exposure
Study NCT05080010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles chemotherapy
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
Study NCT01569685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Tablets, once a day, max 375 mg day (maximal recommended dose)
Study NCT01569685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Tablets, once a day, maximum 200 mg/day (maximum required dose)
Study NCT03238287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical chest compression
Description: In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
Study NCT03238287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manuel chest compression
Description: In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
Study NCT05043467 — intervention group
Intervention type: DRUG
Intervention: Duvie(Lobeglitazone) tab 0.5mg
Description: patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
Study NCT03194373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days
Study NCT03194373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
Study NCT02937350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D6-25-hydroxyvitamin D3
Description: Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
Study NCT03277976 — intervention group
Intervention type: DEVICE
Intervention: PVI using ThermoCool® SmartTouch® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
Study NCT03277976 — intervention group
Intervention type: DEVICE
Intervention: PVI using ThermoCool® SmartTouch SF® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
Study NCT01762852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg
Description: Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
Study NCT01762852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
Study NCT02282644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow sampling
Study NCT01314716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Study NCT01314716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Study NCT01314716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZLI administered via nebulizer three times daily
Study NCT01348997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Onward website + 16 person social network
Description: The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
Study NCT01348997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Onward website + 8 person social network
Description: The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
Study NCT00700271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg or 10 mg tablets.
Study NCT00700271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg capsules.
Study NCT00318760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 0.1 or 0.2 mg oral, one dose
Study NCT00318760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule 1 dose
Study NCT00643643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 25 mg oral tablet once daily for 10 days